25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

GlaxoSmithKline plc
Buy, Hold or Sell?

Let's analyze GlaxoSmithKline plc together

I guess you are interested in GlaxoSmithKline plc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GlaxoSmithKline plc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about GlaxoSmithKline plc

I send you an email if I find something interesting about GlaxoSmithKline plc.

1. Quick Overview

1.1. Quick analysis of GlaxoSmithKline plc (30 sec.)










1.2. What can you expect buying and holding a share of GlaxoSmithKline plc? (30 sec.)

How much money do you get?

How much money do you get?
₱0.03
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
₱3.38
Expected worth in 1 year
₱3.78
How sure are you?
87.1%

+ What do you gain per year?

Total Gains per Share
₱0.99
Return On Investment
0.1%

For what price can you sell your share?

Current Price per Share
₱739.40
Expected price per share
₱636.14 - ₱767.04
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of GlaxoSmithKline plc (5 min.)




Live pricePrice per Share (EOD)
₱739.40
Intrinsic Value Per Share
₱10.35 - ₱11.97
Total Value Per Share
₱13.73 - ₱15.35

2.2. Growth of GlaxoSmithKline plc (5 min.)




Is GlaxoSmithKline plc growing?

Current yearPrevious yearGrowGrow %
How rich?$676.1m$519m$124.3m19.3%

How much money is GlaxoSmithKline plc making?

Current yearPrevious yearGrowGrow %
Making money$1.2b$4.7b-$3.4b-271.0%
Net Profit Margin12.9%49.1%--

How much money comes from the company's main activities?

2.3. Financial Health of GlaxoSmithKline plc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of GlaxoSmithKline plc?

Welcome investor! GlaxoSmithKline plc's management wants to use your money to grow the business. In return you get a share of GlaxoSmithKline plc.

First you should know what it really means to hold a share of GlaxoSmithKline plc. And how you can make/lose money.

Speculation

The Price per Share of GlaxoSmithKline plc is ₱739.40. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of GlaxoSmithKline plc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in GlaxoSmithKline plc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₱3.38. Based on the TTM, the Book Value Change Per Share is ₱0.10 per quarter. Based on the YOY, the Book Value Change Per Share is ₱-0.65 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₱0.14 per quarter.
Based on historical numbers we can estimate the returns while holding a share of GlaxoSmithKline plc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.370.0%0.320.0%1.210.2%0.530.1%0.490.1%
Usd Book Value Change Per Share0.010.0%0.000.0%-0.030.0%0.000.0%0.010.0%
Usd Dividend Per Share0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Total Gains Per Share0.010.0%0.010.0%-0.020.0%0.010.0%0.020.0%
Usd Price Per Share33.88-32.58-31.23-37.38-37.33-
Price to Earnings Ratio23.09-34.08-11.96-28.62-21.57-
Price-to-Total Gains Ratio2,365.36-2,777.70-1,150.13-2,316.79-705.06-
Price to Book Ratio204.39-205.88-248.65-204.06-275.54-
Price-to-Total Gains Ratio2,365.36-2,777.70-1,150.13-2,316.79-705.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share36.30454
Number of shares27
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.010.01
Gains per Quarter (27 shares)0.330.38
Gains per Year (27 shares)1.311.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
111-911-8
221-821-6
322-732-4
432-642-2
543-5530
653-4632
754-3744
864-2846
975-1958
1085010510

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%29.02.00.093.5%29.02.00.093.5%
Book Value Change Per Share4.00.00.0100.0%10.02.00.083.3%17.03.00.085.0%22.09.00.071.0%22.09.00.071.0%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%31.00.00.0100.0%31.00.00.0100.0%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%18.02.00.090.0%27.04.00.087.1%27.04.00.087.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of GlaxoSmithKline plc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1320.102+30%-0.649+592%0.096+37%0.109+21%
Book Value Per Share--3.3763.221+5%2.592+30%3.959-15%3.245+4%
Current Ratio--0.8240.881-6%0.926-11%0.923-11%0.862-4%
Debt To Asset Ratio--0.7630.778-2%0.823-7%0.768-1%0.826-8%
Debt To Equity Ratio--3.0823.372-9%4.522-32%4.181-26%11.038-72%
Dividend Per Share--0.1600.145+10%0.152+5%0.189-16%0.293-46%
Eps--7.4706.437+16%24.605-70%10.889-31%9.985-25%
Free Cash Flow Per Share--0.1650.320-49%0.140+18%0.264-38%0.264-38%
Free Cash Flow To Equity Per Share--0.1650.320-49%-0.043+126%0.097+69%0.097+69%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--11.975--------
Intrinsic Value_10Y_min--10.352--------
Intrinsic Value_1Y_max--1.145--------
Intrinsic Value_1Y_min--1.125--------
Intrinsic Value_3Y_max--3.482--------
Intrinsic Value_3Y_min--3.324--------
Intrinsic Value_5Y_max--5.870--------
Intrinsic Value_5Y_min--5.445--------
Market Cap1508560838169.600-87%2814471470400.0002698836749233.500+4%2593469492499.375+9%3408429991907.974-17%2748111818860.102+2%
Net Profit Margin--0.1490.129+16%0.491-70%0.216-31%0.169-12%
Operating Margin----0%0.197-100%0.189-100%0.205-100%
Operating Ratio--1.0601.080-2%1.040+2%1.117-5%1.115-5%
Pb Ratio219.025+7%204.392205.884-1%248.652-18%204.065+0%275.538-26%
Pe Ratio24.747+7%23.09334.083-32%11.965+93%28.623-19%21.566+7%
Price Per Share739.400+7%690.000663.450+4%636.125+8%761.358-9%760.345-9%
Price To Free Cash Flow Ratio1123.685+7%1048.611877.312+20%169.023+520%-1242.790+219%-801.800+176%
Price To Total Gains Ratio2534.702+7%2365.3562777.700-15%1150.133+106%2316.788+2%705.055+235%
Quick Ratio--0.3580.423-15%0.505-29%0.387-8%0.354+1%
Return On Assets--0.5250.442+19%1.619-68%0.658-20%0.5260%
Return On Equity--2.1201.915+11%9.911-79%3.815-44%4.759-55%
Total Gains Per Share--0.2920.246+18%-0.498+271%0.285+2%0.402-27%
Usd Book Value--676107000.000643369575.000+5%519023825.000+30%843857150.000-20%613550432.258+10%
Usd Book Value Change Per Share--0.0060.005+30%-0.032+592%0.005+37%0.005+21%
Usd Book Value Per Share--0.1660.158+5%0.127+30%0.194-15%0.159+4%
Usd Dividend Per Share--0.0080.007+10%0.007+5%0.009-16%0.014-46%
Usd Eps--0.3670.316+16%1.208-70%0.535-31%0.490-25%
Usd Free Cash Flow--32946100.00063756350.000-48%28122025.000+17%53661390.000-39%34620251.613-5%
Usd Free Cash Flow Per Share--0.0080.016-49%0.007+18%0.013-38%0.013-38%
Usd Free Cash Flow To Equity Per Share--0.0080.016-49%-0.002+126%0.005+69%0.005+69%
Usd Market Cap74070337154.127-87%138190549196.640132512884387.365+4%127339352081.719+9%167353912602.682-17%134932290306.031+2%
Usd Price Per Share36.305+7%33.87932.575+4%31.234+8%37.383-9%37.333-9%
Usd Profit--1496000423.6401285884422.110+16%4770494104.540-69%2207652799.080-32%1720752240.441-13%
Usd Revenue--10054959369.12010026263708.820+0%9352872213.780+8%10457081222.124-4%10204917335.849-1%
Usd Total Gains Per Share--0.0140.012+18%-0.024+271%0.014+2%0.020-27%
 EOD+2 -6MRQTTM+24 -10YOY+22 -135Y+12 -2310Y+16 -19

3.3 Fundamental Score

Let's check the fundamental score of GlaxoSmithKline plc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1524.747
Price to Book Ratio (EOD)Between0-1219.025
Net Profit Margin (MRQ)Greater than00.149
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.358
Current Ratio (MRQ)Greater than10.824
Debt to Asset Ratio (MRQ)Less than10.763
Debt to Equity Ratio (MRQ)Less than13.082
Return on Equity (MRQ)Greater than0.152.120
Return on Assets (MRQ)Greater than0.050.525
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of GlaxoSmithKline plc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.189
Ma 20Greater thanMa 50739.847
Ma 50Greater thanMa 100743.746
Ma 100Greater thanMa 200731.827
OpenGreater thanClose739.400
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About GlaxoSmithKline plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

Fundamental data was last updated by Penke on 2024-11-17 23:37:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit GlaxoSmithKline plc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare GlaxoSmithKline plc to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 14.9% means that $0.15 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GlaxoSmithKline plc:

  • The MRQ is 14.9%. The company is making a huge profit. +2
  • The TTM is 12.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ14.9%TTM12.9%+2.0%
TTM12.9%YOY49.1%-36.3%
TTM12.9%5Y21.6%-8.7%
5Y21.6%10Y16.9%+4.7%
4.3.1.2. Return on Assets

Shows how efficient GlaxoSmithKline plc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare GlaxoSmithKline plc to the Drug Manufacturers - General industry mean.
  • 52.5% Return on Assets means that GlaxoSmithKline plc generated $0.52 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GlaxoSmithKline plc:

  • The MRQ is 52.5%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 44.2%. Using its assets, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ52.5%TTM44.2%+8.3%
TTM44.2%YOY161.9%-117.7%
TTM44.2%5Y65.8%-21.6%
5Y65.8%10Y52.6%+13.2%
4.3.1.3. Return on Equity

Shows how efficient GlaxoSmithKline plc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare GlaxoSmithKline plc to the Drug Manufacturers - General industry mean.
  • 212.0% Return on Equity means GlaxoSmithKline plc generated $2.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GlaxoSmithKline plc:

  • The MRQ is 212.0%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 191.5%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ212.0%TTM191.5%+20.5%
TTM191.5%YOY991.1%-799.6%
TTM191.5%5Y381.5%-190.0%
5Y381.5%10Y475.9%-94.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of GlaxoSmithKline plc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient GlaxoSmithKline plc is operating .

  • Measures how much profit GlaxoSmithKline plc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare GlaxoSmithKline plc to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GlaxoSmithKline plc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY19.7%-19.7%
TTM-5Y18.9%-18.9%
5Y18.9%10Y20.5%-1.6%
4.3.2.2. Operating Ratio

Measures how efficient GlaxoSmithKline plc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.06 means that the operating costs are $1.06 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of GlaxoSmithKline plc:

  • The MRQ is 1.060. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.080. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.060TTM1.080-0.020
TTM1.080YOY1.040+0.040
TTM1.0805Y1.117-0.037
5Y1.11710Y1.115+0.003
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of GlaxoSmithKline plc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if GlaxoSmithKline plc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 0.82 means the company has $0.82 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of GlaxoSmithKline plc:

  • The MRQ is 0.824. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.881. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.824TTM0.881-0.057
TTM0.881YOY0.926-0.045
TTM0.8815Y0.923-0.042
5Y0.92310Y0.862+0.061
4.4.3.2. Quick Ratio

Measures if GlaxoSmithKline plc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare GlaxoSmithKline plc to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.36 means the company can pay off $0.36 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GlaxoSmithKline plc:

  • The MRQ is 0.358. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.423. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.358TTM0.423-0.065
TTM0.423YOY0.505-0.082
TTM0.4235Y0.387+0.036
5Y0.38710Y0.354+0.033
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of GlaxoSmithKline plc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of GlaxoSmithKline plc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare GlaxoSmithKline plc to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.76 means that GlaxoSmithKline plc assets are financed with 76.3% credit (debt) and the remaining percentage (100% - 76.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GlaxoSmithKline plc:

  • The MRQ is 0.763. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.778. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.763TTM0.778-0.015
TTM0.778YOY0.823-0.044
TTM0.7785Y0.768+0.010
5Y0.76810Y0.826-0.058
4.5.4.2. Debt to Equity Ratio

Measures if GlaxoSmithKline plc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare GlaxoSmithKline plc to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 308.2% means that company has $3.08 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GlaxoSmithKline plc:

  • The MRQ is 3.082. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.372. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ3.082TTM3.372-0.290
TTM3.372YOY4.522-1.150
TTM3.3725Y4.181-0.809
5Y4.18110Y11.038-6.857
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings GlaxoSmithKline plc generates.

  • Above 15 is considered overpriced but always compare GlaxoSmithKline plc to the Drug Manufacturers - General industry mean.
  • A PE ratio of 23.09 means the investor is paying $23.09 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GlaxoSmithKline plc:

  • The EOD is 24.747. Based on the earnings, the company is fair priced.
  • The MRQ is 23.093. Based on the earnings, the company is fair priced.
  • The TTM is 34.083. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD24.747MRQ23.093+1.653
MRQ23.093TTM34.083-10.990
TTM34.083YOY11.965+22.119
TTM34.0835Y28.623+5.460
5Y28.62310Y21.566+7.057
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GlaxoSmithKline plc:

  • The EOD is 1,123.685. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 1,048.611. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 877.312. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1,123.685MRQ1,048.611+75.074
MRQ1,048.611TTM877.312+171.299
TTM877.312YOY169.023+708.289
TTM877.3125Y-1,242.790+2,120.102
5Y-1,242.79010Y-801.800-440.990
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of GlaxoSmithKline plc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 204.39 means the investor is paying $204.39 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of GlaxoSmithKline plc:

  • The EOD is 219.025. Based on the equity, the company is expensive. -2
  • The MRQ is 204.392. Based on the equity, the company is expensive. -2
  • The TTM is 205.884. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD219.025MRQ204.392+14.633
MRQ204.392TTM205.884-1.492
TTM205.884YOY248.652-42.768
TTM205.8845Y204.065+1.819
5Y204.06510Y275.538-71.473
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in MXN. All numbers in thousands.

Summary
Total Assets58,066,000
Total Liabilities44,296,000
Total Stockholder Equity14,372,000
 As reported
Total Liabilities 44,296,000
Total Stockholder Equity+ 14,372,000
Total Assets = 58,066,000

Assets

Total Assets58,066,000
Total Current Assets16,764,000
Long-term Assets41,302,000
Total Current Assets
Cash And Cash Equivalents 2,962,000
Short-term Investments 21,000
Net Receivables 7,259,000
Inventory 5,859,000
Total Current Assets  (as reported)16,764,000
Total Current Assets  (calculated)16,101,000
+/- 663,000
Long-term Assets
Property Plant Equipment 9,823,000
Goodwill 6,960,000
Intangible Assets 15,473,000
Long-term Assets Other 1,728,000
Long-term Assets  (as reported)41,302,000
Long-term Assets  (calculated)33,984,000
+/- 7,318,000

Liabilities & Shareholders' Equity

Total Current Liabilities20,345,000
Long-term Liabilities23,951,000
Total Stockholder Equity14,372,000
Total Current Liabilities
Accounts payable 14,245,000
Other Current Liabilities 1,095,000
Total Current Liabilities  (as reported)20,345,000
Total Current Liabilities  (calculated)15,340,000
+/- 5,005,000
Long-term Liabilities
Long-term Liabilities Other 7,170,000
Long-term Liabilities  (as reported)23,951,000
Long-term Liabilities  (calculated)7,170,000
+/- 16,781,000
Total Stockholder Equity
Retained Earnings 8,583,000
Total Stockholder Equity (as reported)14,372,000
Total Stockholder Equity (calculated)8,583,000
+/- 5,789,000
Other
Capital Stock1,348,000
Common Stock Shares Outstanding 4,078,944
Net Invested Capital 14,372,000
Net Working Capital -3,581,000
Property Plant and Equipment Gross 9,823,000



6.2. Balance Sheets Structured

Currency in MXN. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
59,081,000
59,235,000
58,233,000
58,783,000
56,381,000
56,159,000
57,635,000
58,604,000
58,066,000
62,365,000
63,632,000
83,245,000
79,692,000
84,382,000
84,640,000
80,927,000
80,431,000
78,079,000
77,011,000
78,689,000
79,103,000
89,689,000
89,045,000
60,313,000
60,146,000
58,596,000
59,461,000
60,862,000
59,005,000
58,511,000
58,066,000
58,066,00058,511,00059,005,00060,862,00059,461,00058,596,00060,146,00060,313,00089,045,00089,689,00079,103,00078,689,00077,011,00078,079,00080,431,00080,927,00084,640,00084,382,00079,692,00083,245,00063,632,00062,365,00058,066,00058,604,00057,635,00056,159,00056,381,00058,783,00058,233,00059,235,00059,081,000
   > Total Current Assets 
16,711,000
16,787,000
16,426,000
17,656,000
15,907,000
16,423,000
17,044,000
17,418,000
16,927,000
17,524,000
18,228,000
20,990,000
19,491,000
22,023,000
22,978,000
19,881,000
20,247,000
18,524,000
17,566,000
18,254,000
18,674,000
28,988,000
54,188,000
20,249,000
20,769,000
19,719,000
19,348,000
21,240,000
18,644,000
17,205,000
16,764,000
16,764,00017,205,00018,644,00021,240,00019,348,00019,719,00020,769,00020,249,00054,188,00028,988,00018,674,00018,254,00017,566,00018,524,00020,247,00019,881,00022,978,00022,023,00019,491,00020,990,00018,228,00017,524,00016,927,00017,418,00017,044,00016,423,00015,907,00017,656,00016,426,00016,787,00016,711,000
       Cash And Cash Equivalents 
4,897,000
4,509,000
3,986,000
4,743,000
3,833,000
4,004,000
4,046,000
3,793,000
3,874,000
4,132,000
4,123,000
4,305,000
4,707,000
4,769,000
8,166,000
4,283,000
6,292,000
4,757,000
3,503,000
3,453,000
4,274,000
10,967,000
6,465,000
3,606,000
3,723,000
2,890,000
3,140,000
3,177,000
2,746,000
2,790,000
2,962,000
2,962,0002,790,0002,746,0003,177,0003,140,0002,890,0003,723,0003,606,0006,465,00010,967,0004,274,0003,453,0003,503,0004,757,0006,292,0004,283,0008,166,0004,769,0004,707,0004,305,0004,123,0004,132,0003,874,0003,793,0004,046,0004,004,0003,833,0004,743,0003,986,0004,509,0004,897,000
       Short-term Investments 
89,000
88,000
85,000
82,000
78,000
76,000
81,000
80,000
419,000
81,000
84,000
86,000
79,000
86,000
87,000
83,000
78,000
60,000
59,000
61,000
61,000
3,010,000
67,000
3,555,000
4,154,000
4,085,000
3,364,000
3,506,000
2,246,000
1,305,000
21,000
21,0001,305,0002,246,0003,506,0003,364,0004,085,0004,154,0003,555,00067,0003,010,00061,00061,00059,00060,00078,00083,00087,00086,00079,00086,00084,00081,000419,00080,00081,00076,00078,00082,00085,00088,00089,000
       Net Receivables 
5,917,000
6,451,000
6,392,000
6,730,000
5,950,000
6,407,000
6,811,000
7,549,000
5,946,000
6,551,000
6,875,000
8,173,000
6,441,000
8,895,000
7,496,000
8,421,000
6,862,000
7,183,000
7,507,000
8,284,000
7,478,000
8,797,000
6,870,000
8,094,000
6,432,000
7,129,000
6,776,000
8,544,000
5,905,000
6,831,000
7,259,000
7,259,0006,831,0005,905,0008,544,0006,776,0007,129,0006,432,0008,094,0006,870,0008,797,0007,478,0008,284,0007,507,0007,183,0006,862,0008,421,0007,496,0008,895,0006,441,0008,173,0006,875,0006,551,0005,946,0007,549,0006,811,0006,407,0005,950,0006,730,0006,392,0006,451,0005,917,000
       Inventory 
5,102,000
5,417,000
5,743,000
5,661,000
5,557,000
5,659,000
5,943,000
5,788,000
5,476,000
5,678,000
5,959,000
6,776,000
5,947,000
5,952,000
6,396,000
6,440,000
5,996,000
6,216,000
6,330,000
6,244,000
5,783,000
6,003,000
4,664,000
4,659,000
5,146,000
5,355,000
5,512,000
5,480,000
5,498,000
5,702,000
5,859,000
5,859,0005,702,0005,498,0005,480,0005,512,0005,355,0005,146,0004,659,0004,664,0006,003,0005,783,0006,244,0006,330,0006,216,0005,996,0006,440,0006,396,0005,952,0005,947,0006,776,0005,959,0005,678,0005,476,0005,788,0005,943,0005,659,0005,557,0005,661,0005,743,0005,417,0005,102,000
       Other Current Assets 
238,000
322,000
168,000
440,000
181,000
277,000
163,000
208,000
658,000
915,000
1,001,000
1,481,000
941,000
2,321,000
833,000
654,000
195,000
308,000
167,000
212,000
133,000
211,000
36,122,000
335,000
123,000
260,000
0
0
0
0
0
00000260,000123,000335,00036,122,000211,000133,000212,000167,000308,000195,000654,000833,0002,321,000941,0001,481,0001,001,000915,000658,000208,000163,000277,000181,000440,000168,000322,000238,000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
44,841,000
45,404,000
62,255,000
60,201,000
62,359,000
61,662,000
61,046,000
60,184,000
59,555,000
59,445,000
60,435,000
60,429,000
60,701,000
34,857,000
40,064,000
39,377,000
38,877,000
40,113,000
39,622,000
40,361,000
41,306,000
41,302,000
41,302,00041,306,00040,361,00039,622,00040,113,00038,877,00039,377,00040,064,00034,857,00060,701,00060,429,00060,435,00059,445,00059,555,00060,184,00061,046,00061,662,00062,359,00060,201,00062,255,00045,404,00044,841,000000000000
       Property Plant Equipment 
10,808,000
10,812,000
10,662,000
10,633,000
10,860,000
10,661,000
10,823,000
10,923,000
11,058,000
11,292,000
11,408,000
11,700,000
11,314,000
11,402,000
11,431,000
11,205,000
11,006,000
10,633,000
10,589,000
10,667,000
10,672,000
10,704,000
9,153,000
9,650,000
9,620,000
9,414,000
9,315,000
9,454,000
9,957,000
9,867,000
9,823,000
9,823,0009,867,0009,957,0009,454,0009,315,0009,414,0009,620,0009,650,0009,153,00010,704,00010,672,00010,667,00010,589,00010,633,00011,006,00011,205,00011,431,00011,402,00011,314,00011,700,00011,408,00011,292,00011,058,00010,923,00010,823,00010,661,00010,860,00010,633,00010,662,00010,812,00010,808,000
       Goodwill 
5,965,000
5,960,000
5,864,000
5,764,000
5,734,000
5,601,000
5,778,000
5,848,000
5,789,000
6,807,000
7,026,000
11,046,000
10,562,000
10,899,000
10,998,000
10,888,000
10,597,000
10,442,000
10,435,000
10,582,000
10,552,000
10,705,000
5,906,000
7,195,000
7,046,000
6,857,000
6,716,000
6,973,000
6,811,000
6,978,000
6,960,000
6,960,0006,978,0006,811,0006,973,0006,716,0006,857,0007,046,0007,195,0005,906,00010,705,00010,552,00010,582,00010,435,00010,442,00010,597,00010,888,00010,998,00010,899,00010,562,00011,046,0007,026,0006,807,0005,789,0005,848,0005,778,0005,601,0005,734,0005,764,0005,864,0005,960,0005,965,000
       Long Term Investments 
1,248,000
1,325,000
1,263,000
1,116,000
1,101,000
1,148,000
1,269,000
1,614,000
1,563,000
1,642,000
1,689,000
1,926,000
2,156,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000002,156,0001,926,0001,689,0001,642,0001,563,0001,614,0001,269,0001,148,0001,101,0001,116,0001,263,0001,325,0001,248,000
       Intangible Assets 
18,776,000
18,753,000
18,465,000
17,921,000
17,562,000
17,290,000
17,294,000
17,263,000
17,202,000
20,022,000
20,134,000
32,455,000
30,955,000
31,499,000
31,263,000
30,664,000
29,824,000
29,418,000
29,333,000
30,241,000
30,079,000
30,468,000
11,371,000
15,589,000
14,318,000
14,160,000
15,531,000
15,295,000
14,768,000
15,667,000
15,473,000
15,473,00015,667,00014,768,00015,295,00015,531,00014,160,00014,318,00015,589,00011,371,00030,468,00030,079,00030,241,00029,333,00029,418,00029,824,00030,664,00031,263,00031,499,00030,955,00032,455,00020,134,00020,022,00017,202,00017,263,00017,294,00017,290,00017,562,00017,921,00018,465,00018,753,00018,776,000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
1,352,000
1,393,000
1,058,000
1,020,000
2,037,000
946,000
932,000
1,041,000
989,000
1,136,000
1,245,000
1,676,000
1,806,000
1,736,000
1,170,000
1,194,000
1,496,000
1,402,000
1,148,000
0
1,654,000
1,728,000
1,728,0001,654,00001,148,0001,402,0001,496,0001,194,0001,170,0001,736,0001,806,0001,676,0001,245,0001,136,000989,0001,041,000932,000946,0002,037,0001,020,0001,058,0001,393,0001,352,000000000000
> Total Liabilities 
54,118,000
53,642,000
53,809,000
53,954,000
52,892,000
52,569,000
54,612,000
54,881,000
54,394,000
58,994,000
60,665,000
65,185,000
61,335,000
64,285,000
64,503,000
60,302,000
59,623,000
57,069,000
55,433,000
56,941,000
57,761,000
67,057,000
66,405,000
51,597,000
50,050,000
47,284,000
47,302,000
48,243,000
46,210,000
45,282,000
44,296,000
44,296,00045,282,00046,210,00048,243,00047,302,00047,284,00050,050,00051,597,00066,405,00067,057,00057,761,00056,941,00055,433,00057,069,00059,623,00060,302,00064,503,00064,285,00061,335,00065,185,00060,665,00058,994,00054,394,00054,881,00054,612,00052,569,00052,892,00053,954,00053,809,00053,642,00054,118,000
   > Total Current Liabilities 
19,001,000
18,757,000
28,788,000
27,438,000
26,569,000
26,927,000
18,198,000
18,395,000
22,491,000
24,460,000
25,779,000
25,514,000
24,050,000
25,335,000
23,924,000
22,179,000
22,148,000
20,275,000
21,387,000
22,417,000
23,670,000
24,278,000
37,835,000
20,953,000
22,810,000
20,696,000
22,108,000
22,390,000
21,068,000
19,846,000
20,345,000
20,345,00019,846,00021,068,00022,390,00022,108,00020,696,00022,810,00020,953,00037,835,00024,278,00023,670,00022,417,00021,387,00020,275,00022,148,00022,179,00023,924,00025,335,00024,050,00025,514,00025,779,00024,460,00022,491,00018,395,00018,198,00026,927,00026,569,00027,438,00028,788,00018,757,00019,001,000
       Short-term Debt 
18,790,000
18,340,000
18,871,000
19,034,000
2,040,000
17,457,000
28,062,000
0
1,367,000
0
0
0
6,678,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000006,678,0000001,367,000028,062,00017,457,0002,040,00019,034,00018,871,00018,340,00018,790,000
       Short Long Term Debt 
18,790,000
18,340,000
18,871,000
19,034,000
2,040,000
17,457,000
28,062,000
0
1,367,000
0
0
0
6,678,000
0
492,000
0
3,495,000
0
0
0
3,398,000
0
0
0
3,785,000
0
0
0
2,657,000
0
0
002,657,0000003,785,0000003,398,0000003,495,0000492,00006,678,0000001,367,000028,062,00017,457,0002,040,00019,034,00018,871,00018,340,00018,790,000
       Accounts payable 
3,596,000
10,828,000
18,321,000
10,376,000
3,528,000
10,666,000
11,246,000
11,815,000
3,645,000
13,424,000
13,385,000
14,737,000
4,144,000
14,250,000
14,381,000
14,173,000
4,357,000
13,703,000
13,397,000
14,323,000
4,535,000
16,537,000
13,648,000
14,906,000
3,866,000
13,280,000
13,951,000
15,582,000
3,717,000
14,621,000
14,245,000
14,245,00014,621,0003,717,00015,582,00013,951,00013,280,0003,866,00014,906,00013,648,00016,537,0004,535,00014,323,00013,397,00013,703,0004,357,00014,173,00014,381,00014,250,0004,144,00014,737,00013,385,00013,424,0003,645,00011,815,00011,246,00010,666,0003,528,00010,376,00018,321,00010,828,0003,596,000
       Other Current Liabilities 
5,302,000
4,189,000
3,855,000
12,322,000
13,823,000
12,819,000
3,482,000
3,678,000
5,081,000
830,000
816,000
838,000
4,647,000
3,820,000
3,579,000
3,092,000
5,338,000
3,400,000
2,949,000
3,225,000
5,560,000
3,639,000
20,860,000
3,254,000
10,957,000
3,155,000
947,000
1,024,000
1,053,000
1,094,000
1,095,000
1,095,0001,094,0001,053,0001,024,000947,0003,155,00010,957,0003,254,00020,860,0003,639,0005,560,0003,225,0002,949,0003,400,0005,338,0003,092,0003,579,0003,820,0004,647,000838,000816,000830,0005,081,0003,678,0003,482,00012,819,00013,823,00012,322,0003,855,0004,189,0005,302,000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
34,534,000
34,886,000
39,671,000
37,285,000
38,950,000
40,579,000
38,123,000
37,475,000
36,794,000
34,046,000
34,524,000
34,091,000
42,779,000
28,570,000
30,644,000
27,240,000
26,588,000
25,194,000
25,853,000
25,142,000
25,436,000
23,951,000
23,951,00025,436,00025,142,00025,853,00025,194,00026,588,00027,240,00030,644,00028,570,00042,779,00034,091,00034,524,00034,046,00036,794,00037,475,00038,123,00040,579,00038,950,00037,285,00039,671,00034,886,00034,534,000000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
1,250,000
0
0
0
1,117,000
0
0
0
1,015,000
0
0
0
1,008,000
0
0
0
1,207,000
0
0
001,207,0000001,008,0000001,015,0000001,117,0000001,250,000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
6,006,000
6,090,000
6,172,000
4,724,000
5,673,000
5,854,000
6,118,000
5,907,000
5,846,000
5,826,000
5,872,000
6,039,000
6,095,000
6,353,000
7,250,000
6,678,000
6,514,000
6,184,000
6,550,000
5,609,000
7,100,000
7,170,000
7,170,0007,100,0005,609,0006,550,0006,184,0006,514,0006,678,0007,250,0006,353,0006,095,0006,039,0005,872,0005,826,0005,846,0005,907,0006,118,0005,854,0005,673,0004,724,0006,172,0006,090,0006,006,000000000000
> Total Stockholder Equity
1,124,000
1,714,000
811,000
1,294,000
-68,000
-69,000
3,679,000
4,476,000
4,360,000
4,014,000
3,614,000
11,772,000
11,405,000
13,094,000
13,593,000
14,286,000
14,587,000
14,865,000
15,377,000
15,426,000
15,055,000
16,181,000
16,374,000
9,152,000
10,598,000
11,820,000
12,691,000
13,133,000
13,347,000
13,840,000
14,372,000
14,372,00013,840,00013,347,00013,133,00012,691,00011,820,00010,598,0009,152,00016,374,00016,181,00015,055,00015,426,00015,377,00014,865,00014,587,00014,286,00013,593,00013,094,00011,405,00011,772,0003,614,0004,014,0004,360,0004,476,0003,679,000-69,000-68,0001,294,000811,0001,714,0001,124,000
   Common Stock
1,342,000
1,343,000
1,343,000
1,343,000
1,343,000
1,343,000
1,343,000
1,344,000
1,345,000
1,345,000
1,345,000
1,345,000
1,346,000
1,346,000
1,346,000
1,346,000
1,346,000
1,346,000
1,347,000
1,347,000
1,347,000
1,347,000
1,347,000
1,347,000
1,347,000
1,348,000
0
0
0
0
0
000001,348,0001,347,0001,347,0001,347,0001,347,0001,347,0001,347,0001,347,0001,346,0001,346,0001,346,0001,346,0001,346,0001,346,0001,345,0001,345,0001,345,0001,345,0001,344,0001,343,0001,343,0001,343,0001,343,0001,343,0001,343,0001,342,000
   Retained Earnings Total Equity0000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000
   Other Stockholders Equity 
2,092,000
2,282,000
2,314,000
2,289,000
2,490,000
1,911,000
1,974,000
2,164,000
2,046,000
1,956,000
1,916,000
1,997,000
1,831,000
2,120,000
2,347,000
2,605,000
2,666,000
3,523,000
3,352,000
2,996,000
1,660,000
1,761,000
1,764,000
1,773,000
1,019,000
1,368,000
0
0
0
0
0
000001,368,0001,019,0001,773,0001,764,0001,761,0001,660,0002,996,0003,352,0003,523,0002,666,0002,605,0002,347,0002,120,0001,831,0001,997,0001,916,0001,956,0002,046,0002,164,0001,974,0001,911,0002,490,0002,289,0002,314,0002,282,0002,092,000



6.3. Balance Sheets

Currency in MXN. All numbers in thousands.




6.4. Cash Flows

Currency in MXN. All numbers in thousands.




6.5. Income Statements

Currency in GBP. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in MXN. All numbers in thousands.

Gross Profit (+$)
totalRevenue30,328,000
Cost of Revenue-8,565,000
Gross Profit21,763,00021,763,000
 
Operating Income (+$)
Gross Profit21,763,000
Operating Expense-22,983,000
Operating Income7,345,000-1,220,000
 
Operating Expense (+$)
Research Development6,223,000
Selling General Administrative9,385,000
Selling And Marketing Expenses-
Operating Expense22,983,00015,608,000
 
Net Interest Income (+$)
Interest Income48,000
Interest Expense-725,000
Other Finance Cost-58,000
Net Interest Income-735,000
 
Pretax Income (+$)
Operating Income7,345,000
Net Interest Income-735,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)6,064,0007,345,000
EBIT - interestExpense = -725,000
4,928,000
5,653,000
Interest Expense725,000
Earnings Before Interest and Taxes (EBIT)-6,789,000
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax6,064,000
Tax Provision-756,000
Net Income From Continuing Ops5,308,0005,308,000
Net Income4,928,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-735,000
 

Technical Analysis of GlaxoSmithKline plc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of GlaxoSmithKline plc. The general trend of GlaxoSmithKline plc is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine GlaxoSmithKline plc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GlaxoSmithKline plc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 767.04 < 767.04 < 767.04.

The bearish price targets are: 665.00 > 636.14 > 636.14.

Tweet this
GlaxoSmithKline plc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GlaxoSmithKline plc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GlaxoSmithKline plc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GlaxoSmithKline plc. The current macd is -13.22955795.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the GlaxoSmithKline plc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for GlaxoSmithKline plc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the GlaxoSmithKline plc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
GlaxoSmithKline plc Daily Moving Average Convergence/Divergence (MACD) ChartGlaxoSmithKline plc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GlaxoSmithKline plc. The current adx is 60.71.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy GlaxoSmithKline plc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
GlaxoSmithKline plc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GlaxoSmithKline plc. The current sar is 746.91.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
GlaxoSmithKline plc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GlaxoSmithKline plc. The current rsi is 52.19. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
GlaxoSmithKline plc Daily Relative Strength Index (RSI) ChartGlaxoSmithKline plc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GlaxoSmithKline plc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the GlaxoSmithKline plc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
GlaxoSmithKline plc Daily Stochastic Oscillator ChartGlaxoSmithKline plc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GlaxoSmithKline plc. The current cci is -0.61377442.

GlaxoSmithKline plc Daily Commodity Channel Index (CCI) ChartGlaxoSmithKline plc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GlaxoSmithKline plc. The current cmo is 11.90.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
GlaxoSmithKline plc Daily Chande Momentum Oscillator (CMO) ChartGlaxoSmithKline plc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GlaxoSmithKline plc. The current willr is -27.08884577.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that GlaxoSmithKline plc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
GlaxoSmithKline plc Daily Williams %R ChartGlaxoSmithKline plc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of GlaxoSmithKline plc.

GlaxoSmithKline plc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GlaxoSmithKline plc. The current atr is 11.26.

GlaxoSmithKline plc Daily Average True Range (ATR) ChartGlaxoSmithKline plc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GlaxoSmithKline plc. The current obv is 28,219.

GlaxoSmithKline plc Daily On-Balance Volume (OBV) ChartGlaxoSmithKline plc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GlaxoSmithKline plc. The current mfi is 13.10.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
GlaxoSmithKline plc Daily Money Flow Index (MFI) ChartGlaxoSmithKline plc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GlaxoSmithKline plc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-12ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

GlaxoSmithKline plc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GlaxoSmithKline plc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.189
Ma 20Greater thanMa 50739.847
Ma 50Greater thanMa 100743.746
Ma 100Greater thanMa 200731.827
OpenGreater thanClose739.400
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of GlaxoSmithKline plc with someone you think should read this too:
  • Are you bullish or bearish on GlaxoSmithKline plc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about GlaxoSmithKline plc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GlaxoSmithKline plc

I send you an email if I find something interesting about GlaxoSmithKline plc.


Comments

How you think about this?

Leave a comment

Stay informed about GlaxoSmithKline plc.

Receive notifications about GlaxoSmithKline plc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.